Annovis Bio Inc. (NYSE: ANVS) announced it has regained compliance with New York Stock Exchange continued listing standards after falling below required thresholds in 2025.

The biotechnology company received notice from the NYSE on March 26, 2025, that it was not compliant with Section 802.01B of the NYSE Listed Company Manual. The company's average global market capitalization had fallen below $50 million over a consecutive 30-trading-day period while its stockholders' equity was also below $50 million.

The NYSE accepted Annovis's plan to regain compliance on June 19, 2025, and granted an 18-month cure period from the original notice date. The company executed corrective actions to restore its market capitalization and stockholders' equity above required thresholds and provided quarterly progress updates to the exchange.

The NYSE has confirmed that Annovis has regained full compliance with all applicable continued listing requirements. The company's common stock will continue trading on the NYSE under ticker symbol "ANVS."

"We are pleased to have regained full NYSE compliance in just 12 months, well ahead of the 18-month deadline," said Alexander Morin, Director of Strategic Communications.

Annovis is a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. The company is based in Malvern, Pennsylvania.